Elsevier

Pathology

Volume 39, Issue 1, February 2007, Pages 46-54
Pathology

Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium

https://doi.org/10.1080/00313020601146822Get rights and content

Summary

Endometrial carcinoma, endometrial stromal tumours and mixed malignant mesodermal tumours (MMMT) develop along distinctive molecular genetic pathways. Two distinctive types of endometrial carcinoma are distinguished, type I and type II, which develop along distinctive pathways and show different clinical behaviour and histological features. Type I carcinomas show endometrioid histology, are oestrogen- related and develop from atypical endometrial hyperplasia. The molecular tumorigenesis is comparable to colorectal carcinoma with a step-like progression and an accumulation of genetic alterations. Alterations of PTEN, K-Ras mutations and microsatellite instability are frequent and early events in type I carcinoma, whereas p53 mutations occur during progression to grade 3 carcinoma. Serous and clear cell carcinomas are considered type II carcinomas which are mostly unrelated to oestrogen. p53 mutations occur in almost all serous carcinomas and seem to occur early, leading to massive chromosomal instability and rapid tumour progression. Gene expression profiling has supported this dualistic model of endometrial carcinoma. There is evidence of molecular differences between serous and clear cell carcinomas as well as between endometrioid carcinomas with and without microsatellite instability. A dualistic model of tumorigenesis may be also suggested for endometrial stromal tumours. Endometrial stromal sarcomas (ESS; type I endometrial sarcoma) are oestrogen-related and seem to develop from endometrial stromal nodules (ESN). They are histologically and genetically distinct from undifferentiated endometrial sarcoma (UES) which seem to be mostly unrelated to oestrogen (type II endometrial sarcoma). ESS and ESN share the fusion gene JAZF1/JJAZ1 caused by a t(7;17)(p15;q21) translocation, whereas UES lacks a distinctive molecular alteration so far. In MMMT, which is considered a metaplastic carcinoma, p53 alteration occurs early, before clonal expansion and acquisition of genetic diversity during progression.

References (82)

  • EstellerM. et al.

    hMLH1 promoter hypermethylation is an early event in human endometrial tumorigen- esis

    Am J Pathol

    (1999)
  • WatsonP. et al.

    The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer

    Am J Med

    (1994)
  • IoffeO.B. et al.

    Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium

    Hum Pathol

    (1998)
  • HolcombK. et al.

    E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium

    Obstet Gynecol

    (2002)
  • AnH.J. et al.

    Molecular characterization of uterine clear cell carcinoma

    Mod Pathol

    (2004)
  • AmantF. et al.

    Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma

    Gynecol Oncol

    (2004)
  • HrzenjakA. et al.

    JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin- embedded tissue

    J Mol Diagn

    (2005)
  • MicciF. et al.

    Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/ JJAZ1 gene fusion in t(7;17)

    Cancer Genet Cytogenet

    (2003)
  • TalliniG. et al.

    HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes

    Lab Invest

    (2000)
  • GunawanB. et al.

    Identification of a BAC clone overlapping the t(6p12.3) breakpoint in the cell line ESS-1 derived from an endometrial stromal sarcoma

    Cancer Genet Cytogenet

    (2003)
  • HalbwedlI. et al.

    Chromosomal alterations in low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization

    Gynecol Oncol

    (2005)
  • MoinfarF. et al.

    Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues

    Gynecol Oncol

    (2004)
  • TaylorN.P. et al.

    DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis

    Mod Pathol

    (2006)
  • BlomR. et al.

    Malignant mixed Mullerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases

    Gynecol Oncol

    (1998)
  • SwisherE.M. et al.

    The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma

    Gynecol Oncol

    (1996)
  • KinzlerK.W. et al.

    Cancer-susceptibility genes. Gatekeepers and caretakers

    Nature

    (1997)
  • SpruckC.H. et al.

    Two molecular pathways to transitional cell carcinoma of the bladder

    Cancer Res

    (1994)
  • PeruchoM.

    Microsatellite instability: the mutator that mutates the other mutator

    Nat Med

    (1996)
  • BennicelliJ.L. et al.

    Chromosomal translocations and sarcomas

    Curr Opin Oncol

    (2002)
  • Schneider-StockR. et al.

    MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas

    J Cancer Res Clin Oncol

    (1998)
  • LaxS.F. et al.

    A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses

    Verh Dtsch Ges Pathol

    (1997)
  • SalvesenH.B. et al.

    Molecular pathogenesis and prognostic factors in endometrial carcinoma

    Apmis

    (2002)
  • ShermanM.E. et al.

    Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas

    Mod Pathol

    (1997)
  • PotischmanN. et al.

    Case-control study of endogenous steroid hormones and endometrial cancer

    J Natl Cancer Inst

    (1996)
  • WeiderpassE. et al.

    Risk of endometrial cancer following estrogen replacement with and without progestins

    J Natl Cancer Inst

    (1999)
  • AbelerV.M. et al.

    Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern

    Cancer

    (1996)
  • MutterG.L. et al.

    Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

    J Natl Cancer Inst

    (2000)
  • DugganB.D. et al.

    Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma

    Cancer Res

    (1994)
  • LevineR.L. et al.

    PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma

    Cancer Res

    (1998)
  • MutterG.L. et al.

    Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry

    J Pathol

    (2000)
  • Cited by (60)

    • A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome

      2019, Annals of Diagnostic Pathology
      Citation Excerpt :

      A study undertaken by Broaddus et al [33] illustrated that in their cohort, all NEECs associated with LS harboured MSH2 mutations and that less NEECs were identified in LS patients than compared to the general population [33]. Microsatellites are one to five base pair sequences on DNA that are repeated a number of times and it is these short-tandem repeats that are prone to alterations in mismatch repair [16,29,30]. A repeat of CA is the most commonly occurring microsatellite identified in humans [16].

    • Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components

      2017, Human Pathology
      Citation Excerpt :

      Furthermore, although the 2014 WHO criteria defined that even the presence of 5% of each component is considered sufficient for categorizing tumors as mixed endometrial tumors, several authors suggested a different percentage of histotype components [1]. This distinction reflects the association of these components, with distinctive pathways leading to a different clinical behavior and histologic features [13-16]. In fact, although classical endometrial type I carcinomas are estrogen related and characterized by alteration of PTEN, K-Ras mutations, microsatellite instability, and late evidence of p53 mutations [25-27]; on the other hand, endometrial type II carcinomas are mostly unrelated to estrogen and with early p53 mutations [8,9].

    • Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis

      2013, Human Pathology
      Citation Excerpt :

      Although ECSs are more aggressive than other endometrial carcinomas, the underlying molecular alterations remain poorly understood. Mutations in and loss of heterozygosity for TP53 (tumor protein p53) occur frequently in these endometrial tumors [4] together with p16 overexpression [1]. Moreover, mutations in several oncogenes have been described in some cases, such as in PIK3CA (phosphoinositide-3- kinase, catalytic, alpha polypeptide) and KRAS [5].

    • Searching for molecular targets in sarcoma

      2012, Biochemical Pharmacology
    • Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma

      2019, Brachytherapy
      Citation Excerpt :

      While greater than 90% of patients with serous carcinoma harbor TP53 mutations, typically accompanied by loss of heterozygosity and nuclear protein overexpression (17), only 30–40% of patients with clear cell carcinoma harbor p53 mutations (18). Furthermore, the frequency of microsatellite instability (15%) and PTEN (30%) mutations in clear cell carcinoma is higher than that in serous carcinoma (5% and 10%, respectively) (19, 20). Moreover, DeLair et al. (21) recently evaluated the genetic heterogeneity of clear cell carcinomas and showed that it can be classified into the previously demonstrated four molecular subtypes for endometrioid and serous carcinomas.

    View all citing articles on Scopus
    View full text